 BOULDER, Colo., April 16, 2021 GLOBE NEWSWIRE -- Brickell Biotech, Inc. Brickell or the Company Nasdaq: BBI, a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from the US Phase 3 open-label long-term 12-month safety study of sofpironium bromide gel, 5 and 15 were selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatologys AAD 2021 Virtual Meeting Experience VMX being held April 23 25, 2021. Also, as one of the top twelve late-breaking research abstracts, Brickell has been invited to participate in a live QA session on April 24th from 2:00 PM 3:00 PM CT. 